Author: Cardiol Therapeutics Inc. (NASDAQ: CRDL)

Posted Date:

April 29, 2026

Phase III Trial Enrollment Reached (75%) for Promising Anti-Inflammatory and Anti-Fibrotic Cardiac Therapies by Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL)

April 29, 2026
Correction: Positive Results on MAVERIC Phase 2 and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL)

April 27, 2026
$30 Billion Per Year US Heart Failure Market Presents Huge Opportunity for Promising Drugs Advancing with Positive Trial Results for Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL)

April 13, 2026